Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026)
Cellectis (CLLS) posted quarterly Total Non-Current Liabilities of $94.8 million for Q1 2026, up 11.08% year-over-year from $85.3 million in Q1 2025, and down 8.05% quarter-over-quarter from $103.1 million in Q4 2025.
Cellectis (CLLS) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Cellectis' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $94.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 11.08% year-over-year to $94.8 million; the TTM figure through Mar 2026 stood at $94.8 million (up 11.08% YoY), while the FY2025 annual figure was $103.1 million, up 19.51% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $94.8 million, down from $103.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $105.4 million in Q1 2024, with the low at $70.4 million in Q1 2023.
- The 5-year median for Total Non-Current Liabilities is $89.6 million (2023), against an average of $90.1 million.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities dropped 24.91% in 2022, then jumped 49.67% in 2024.
- Cellectis' Total Non-Current Liabilities stood at $72.3 million in 2022, then surged by 30.65% to $94.4 million in 2023, then slipped by 8.67% to $86.2 million in 2024, then grew by 19.51% to $103.1 million in 2025, then declined by 8.05% to $94.8 million in 2026.
- Business Quant data shows CLLS's Total Non-Current Liabilities at $94.8 million in Q1 2026, $103.1 million in Q4 2025, and $94.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 94.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.77 Mn |
| Dec 31, 2025 | 103.07 Mn |
| Sep 30, 2025 | 93.99 Mn |
| Jun 30, 2025 | 89.42 Mn |
| Mar 31, 2025 | 85.31 Mn |
| Dec 31, 2024 | 86.24 Mn |
| Sep 30, 2024 | 100.80 Mn |
| Jun 30, 2024 | 98.90 Mn |
| Mar 31, 2024 | 105.45 Mn |
| Dec 31, 2023 | 94.43 Mn |
| Sep 30, 2023 | 89.63 Mn |
| Jun 30, 2023 | 89.07 Mn |
| Mar 31, 2023 | 70.45 Mn |
| Dec 31, 2022 | 72.28 Mn |
| Sep 30, 2022 | 80.94 Mn |
| Jun 30, 2022 | 85.08 Mn |
| Mar 31, 2022 | 91.80 Mn |
| Dec 31, 2021 | 96.25 Mn |
| Sep 30, 2021 | 101.14 Mn |
| Jun 30, 2021 | 103.80 Mn |